During CNBC’s ‘Mad Money Lightning Round,’ Jim Cramer provided his perspective on several companies, offering insights into their potential and risks.
When asked about ADMA Biologics (ADMA), a biotechnology company focused on treating immune-compromised patients, Cramer stated, “This is a very speculative situation.” However, he added, “Any time there’s immunity-compromised patients, there’s some big money down the road.” ADMA Biologics recently reported better-than-expected second-quarter financial results and raised its revenue guidance for 2024 and 2025. The company surpassed analyst expectations for both earnings and revenue.
Cramer expressed concern about MP Materials (MP), a rare earth materials company, stating, “This is one of those situations that is very difficult. If they don’t pull out of the tailspin of losses, then it just doesn’t matter.” MP Materials had also reported better-than-expected second-quarter sales, exceeding analyst consensus estimates for both earnings and revenue.
Regarding Delcath Systems (DCTH), a company developing liver-directed therapies for cancer, Cramer cautioned, “There’s no investing. At this point, it is speculating.” Delcath Systems recently announced positive results from an independent study on its therapy for uveal melanoma patients.
On Thursday, ADMA Biologics shares closed down 0.1% at $17.22, MP Materials shares rose 3.2% to $12.90, and Delcath Systems shares gained 1.2% to $10.77.
